Vaccination COVID-19 Anaphylaxis

Report 9618 - Appendix Anaphylaxis: Recommendations for prioritization at-risk groups for SARS-CoV-2 Vaccination (Phase 1b) (v2)

In this scientific advisory report, which offers guidance to public health policy-makers, the Belgian Superior Health Council highlights the priorities for vaccinating at-risk patients against COVID-19 (Phase Ib). This report aims at providing the Belgian Immunization Strategy and Operationalization Taskforce and general practitioners with specific recommendations on strategic COVID-19 vaccination in Belgium.

This appendix describes allergic reactions, including anaphylaxis following COVID-19 vaccination.

With contributions from Pr. Vito Sabato, Tim De Cloet, Pr. Didier Ebo, Pr. Pierre Van Damme, Pr. Antoine Froidure (on behalf of BelSACI), Pr. Jean-Michel Dogné – Version approved by the NITAG Vaccination during the meeting of 21/01/2021.